FDA Briefing Docs Appear Positive For Abbott's Absorb, But Adverse Events Highlighted

An FDA panel meets March 15 to discuss Abbott's PMA for the firm's fully absorbable Absorb scaffold. Pre-meeting materials give a generally positive view of the device, but they highlight some elevated adverse-event rates.

[Editor's note: FDA's Circulatory System Devices panel voted in support of Abbott's Absorb on March 15. See our detailed coverage. (See Also see "Despite Panel Thumbs-Up, Analysts Downplay Absorb Market Impact" - Medtech Insight, 15 March, 2016..)]

As FDA gears up to hold an advisory panel meeting March 15 to discuss Abbott Laboratories Inc. 's fully...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation